Modular Medical Loss Falls to $0.90 per Share Amid Going-Concern Doubts
Key Facts
Modular Medical reported a basic and diluted loss of $0.90 per share for the three months ended September 30, 2026, compared with a loss of $4.21 per share in the same period of 2025, according to its filing with the U.S. Securities and Exchange Commission. The company posted a net loss of $7.103 million for the quarter, versus $7.790 million a year earlier. The narrower net loss reflected lower research and development expenses, partly offset by higher general and administrative expenses. The filing also said the company had a cash balance of $5.1 million, while its accumulated deficit reached $126.6 million as of September 30. The company said these conditions raise substantial doubt about its ability to continue as a going concern for at least one year from the report’s issuance date.
Quarterly research and development expenses fell to $3.926 million from $5.593 million in the same period of 2025. Modular Medical attributed the decline primarily to a roughly $0.6 million decrease in employee costs and a roughly $0.5 million decrease in materials and supplies. Consulting costs also fell by roughly $0.4 million, as did stock-based compensation. By contrast, general and administrative expenses rose to $3.215 million from $2.236 million, an increase of $979,000, or 43.8%. The company said the increase was primarily related to roughly $1.2 million in higher consulting fees, including for marketing and sales, investor relations and capital markets activities.
Operating cash use weighed on the broader liquidity picture: Modular Medical used about $12.3 million in operating activities during the six months ended September 30, 2026, compared with about $10.8 million in the same period of 2025. On the product front, the Pivot insulin delivery system received clearance from the U.S. Food and Drug Administration in April 2026, and the company began initial shipments in the United States in June. However, the filing said it had recorded no revenue from those low-volume shipments as of the disclosure date. The company expected research and development expenses to remain stable or rise modestly in the second half of fiscal 2027. It also expected general and administrative expenses to increase as it expands its sales, marketing and management teams to support commercialization of the Pivot pump during the fiscal year.
Bayview Acquisition reported a net loss of $132,925 in the third quarter of 2026, compared with a loss of $17,903 in the same period of 2025. Per-share results varied by class: basic and diluted income per redeemable share was $0.14, while the loss per nonredeemable share was $0.15. For the nine months ended September 30, the company recorded a net loss of $876,060, following net income of $240,173 in the same period of 2025. According to its filing, Bayview had not commenced operations as of September 30, 2026, and had generated no revenue, as its activities were focused on pursuing a merger or business combination. It had $50,976 in available cash and a working capital deficit of $5,044,855, conditions that management said raise substantial doubt about the company’s ability to continue as a going concern.
Bayview’s proposed transaction with Oabay faces a complex regulatory path after Nasdaq suspended trading in the company’s securities effective at the open on July 7, 2026, following the failure to complete the merger by the June 19 deadline. On October 30, Nasdaq notified the company that its board had declined to review the delisting decisions and that it would proceed with removing the securities from listing; Form 25-NSE had not been filed as of the report date. Bayview acknowledged that the trading suspension and potential delisting could adversely affect the merger if the agreement were not amended or some of its conditions waived. The company had deposited $50,000 into the trust account on October 16 to extend the deadline to complete the transaction from October 19 to November 19, 2026. This was the fifth of six possible extensions under the company’s amended charter, with the new deadline approaching.
In trading on the day before the news date, Modular Medical shares closed at $1.8 on November 17, according to EL7 data. Reliable open data to verify the session high or low was unavailable, so this account of the stock’s move is limited to its closing price. Liquidity and going-concern indicators remain among the key elements of Modular Medical’s disclosure, alongside the improvement in its quarterly loss. For Bayview, the near-term milestone is the extended November 19 deadline to complete the merger, alongside ongoing Nasdaq delisting proceedings. The filing did not specify a future outcome for the transaction or its ultimate effect on the company.